25 XP   0   0   10

Lavipharm S.A
Buy, Hold or Sell?

Let's analyse Lavipharm together

PenkeI guess you are interested in Lavipharm S.A. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Lavipharm S.A. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Lavipharm S.A

I send you an email if I find something interesting about Lavipharm S.A.

Quick analysis of Lavipharm (30 sec.)










What can you expect buying and holding a share of Lavipharm? (30 sec.)

How much money do you get?

How much money do you get?
‚ā¨0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
‚ā¨0.25
Expected worth in 1 year
‚ā¨0.31
How sure are you?
80.0%

+ What do you gain per year?

Total Gains per Share
‚ā¨0.06
Return On Investment
6.7%

For what price can you sell your share?

Current Price per Share
‚ā¨0.89
Expected price per share
‚ā¨0.78 - ‚ā¨1.0052903225807
How sure are you?
50%

1. Valuation of Lavipharm (5 min.)




Live pricePrice per Share (EOD)

‚ā¨0.89

Intrinsic Value Per Share

‚ā¨-0.88 - ‚ā¨-1.04

Total Value Per Share

‚ā¨-0.62 - ‚ā¨-0.78

2. Growth of Lavipharm (5 min.)




Is Lavipharm growing?

Current yearPrevious yearGrowGrow %
How rich?$45.8m$43.1m$2.6m5.8%

How much money is Lavipharm making?

Current yearPrevious yearGrowGrow %
Making money$2m$893.1k$1.1m55.4%
Net Profit Margin3.7%1.8%--

How much money comes from the company's main activities?

3. Financial Health of Lavipharm (5 min.)




What can you expect buying and holding a share of Lavipharm? (5 min.)

Welcome investor! Lavipharm's management wants to use your money to grow the business. In return you get a share of Lavipharm.

What can you expect buying and holding a share of Lavipharm?

First you should know what it really means to hold a share of Lavipharm. And how you can make/lose money.

Speculation

The Price per Share of Lavipharm is ‚ā¨0.89. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Lavipharm.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Lavipharm, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ‚ā¨0.25. Based on the TTM, the Book Value Change Per Share is ‚ā¨0.01 per quarter. Based on the YOY, the Book Value Change Per Share is ‚ā¨0.30 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ‚ā¨0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Lavipharm.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 ‚ā¨% of Price per Share‚ā¨% of Price per Share‚ā¨% of Price per Share‚ā¨% of Price per Share‚ā¨% of Price per Share
Usd Eps0.011.3%0.011.3%0.010.6%0.021.7%0.00-0.2%
Usd Book Value Change Per Share0.021.8%0.021.8%0.3236.0%0.088.9%0.033.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.021.8%0.021.8%0.3236.0%0.088.9%0.033.1%
Usd Price Per Share0.85-0.85-0.41-0.52-0.33-
Price to Earnings Ratio71.42-71.42-77.29-49.97-27.05-
Price-to-Total Gains Ratio53.62-53.62-1.28-28.17-20.18-
Price to Book Ratio3.12-3.12-1.60--2.81--1.80-
Price-to-Total Gains Ratio53.62-53.62-1.28-28.17-20.18-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.953101
Number of shares1049
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.020.08
Usd Total Gains Per Share0.020.08
Gains per Quarter (1049 shares)16.6883.38
Gains per Year (1049 shares)66.71333.52
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1067570334324
201331240667658
3020019101001992
40267258013341326
50334325016681660
60400392020011994
70467459023352328
80534526026682662
90600593030022996
100667660033353330

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%8.02.00.080.0%8.02.00.080.0%
Book Value Change Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%8.02.00.080.0%8.02.00.080.0%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.010.00.0%0.00.010.00.0%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%8.02.00.080.0%8.02.00.080.0%

Fundamentals of Lavipharm

About Lavipharm S.A

Lavipharm S.A. engages in the research, development, manufacturing, import, marketing, sale, and wholesaling of pharmaceutical, dermocosmetic, and healthcare products in Greece and internationally. The company offers pharmaceutical products for cardiology, chronic pain and oncology, central nervous system, respiratory system, gastrointestinal system, and urology; and over the counter (OTC) drugs, such as antiseptics, anagelsics, and anti-lice treatment products. It also provides a range of skincare products focused on health. The company was founded in 1911 and is based in Paiania, Greece.

Fundamental data was last updated by Penke on 2024-06-08 01:28:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Lavipharm S.A.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit¬†Lavipharm earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare¬†Lavipharm to the¬† Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 3.7%¬†means that¬†€0.04 for each €1¬†in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Lavipharm S.A:

  • The MRQ is 3.7%. The company is making a profit. +1
  • The TTM is 3.7%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ3.7%TTM3.7%0.0%
TTM3.7%YOY1.8%+1.9%
TTM3.7%5Y6.3%-2.6%
5Y6.3%10Y-2.5%+8.8%
1.1.2. Return on Assets

Shows how efficient Lavipharm is using its assets to generate profit.

  • Above 5% is considered healthy¬†but always compare¬†Lavipharm to the¬† Drug Manufacturers - Specialty & Generic industry mean.
  • 1.6% Return on Assets means that¬†Lavipharm generated¬†€0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Lavipharm S.A:

  • The MRQ is 1.6%. Using its assets, the company is less efficient in making profit.
  • The TTM is 1.6%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ1.6%TTM1.6%0.0%
TTM1.6%YOY0.7%+0.9%
TTM1.6%5Y4.1%-2.5%
5Y4.1%10Y2.0%+2.1%
1.1.3. Return on Equity

Shows how efficient Lavipharm is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare¬†Lavipharm to the¬† Drug Manufacturers - Specialty & Generic industry mean.
  • 4.4% Return on Equity means Lavipharm generated €0.04¬†for each¬†€1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Lavipharm S.A:

  • The MRQ is 4.4%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 4.4%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ4.4%TTM4.4%0.0%
TTM4.4%YOY2.1%+2.3%
TTM4.4%5Y1.3%+3.1%
5Y1.3%10Y0.6%+0.6%

1.2. Operating Efficiency of Lavipharm S.A.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Lavipharm is operating .

  • Measures how much profit Lavipharm makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare¬†Lavipharm to the¬† Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0%¬†means the company generated €0.00 ¬†for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Lavipharm S.A:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY8.8%-8.8%
TTM-5Y9.1%-9.1%
5Y9.1%10Y0.9%+8.2%
1.2.2. Operating Ratio

Measures how efficient Lavipharm is keeping operating costs low.

  • Below 1 is considered healthy (always compare to¬† Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.46 means that the operating costs are €1.46 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Lavipharm S.A:

  • The MRQ is 1.462. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.462. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.462TTM1.4620.000
TTM1.462YOY1.529-0.066
TTM1.4625Y1.283+0.180
5Y1.28310Y1.410-0.127

1.3. Liquidity of Lavipharm S.A.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Lavipharm is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to¬† Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.28¬†means the company has €1.28 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Lavipharm S.A:

  • The MRQ is 1.275. The company is just able to pay all its short-term debts.
  • The TTM is 1.275. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.275TTM1.2750.000
TTM1.275YOY0.997+0.278
TTM1.2755Y1.169+0.106
5Y1.16910Y0.916+0.254
1.3.2. Quick Ratio

Measures if Lavipharm is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but¬†always compare¬†Lavipharm to the¬† Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.61¬†means the company can pay off €0.61 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Lavipharm S.A:

  • The MRQ is 0.606. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.606. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.606TTM0.6060.000
TTM0.606YOY0.708-0.102
TTM0.6065Y0.699-0.093
5Y0.69910Y0.578+0.121

1.4. Solvency of Lavipharm S.A.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Lavipharm assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare¬†Lavipharm to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.63¬†means that Lavipharm assets are¬†financed with 62.7% credit (debt) and the remaining percentage (100% - 62.7%)¬†is financed by its owners/shareholders.¬†

Let's take a look of the Debt to Asset Ratio trends of Lavipharm S.A:

  • The MRQ is 0.627. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.627. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.627TTM0.6270.000
TTM0.627YOY0.647-0.020
TTM0.6275Y0.999-0.372
5Y0.99910Y1.293-0.294
1.4.2. Debt to Equity Ratio

Measures if Lavipharm is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but¬†always compare¬†Lavipharm to the¬† Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 168.5% means that company has €1.69 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Lavipharm S.A:

  • The MRQ is 1.685. The company is just able to pay all its debts with equity.
  • The TTM is 1.685. The company is just able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ1.685TTM1.6850.000
TTM1.685YOY1.835-0.149
TTM1.6855Y0.704+0.981
5Y0.70410Y0.352+0.352

2. Market Valuation of Lavipharm S.A

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures¬†how much money you pay¬†for each share for¬†every €1 in earnings Lavipharm generates.

  • Above 15 is considered overpriced but¬†always compare¬†Lavipharm to the¬† Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 71.42 means the investor is paying €71.42¬†for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Lavipharm S.A:

  • The EOD is 79.852. Based on the earnings, the company is expensive. -2
  • The MRQ is 71.418. Based on the earnings, the company is expensive. -2
  • The TTM is 71.418. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD79.852MRQ71.418+8.434
MRQ71.418TTM71.4180.000
TTM71.418YOY77.292-5.874
TTM71.4185Y49.966+21.452
5Y49.96610Y27.045+22.920
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Lavipharm S.A:

  • The EOD is -38.978. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -34.861. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -34.861. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-38.978MRQ-34.861-4.117
MRQ-34.861TTM-34.8610.000
TTM-34.861YOY-1.998-32.864
TTM-34.8615Y12.996-47.857
5Y12.99610Y6.498+6.498
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Lavipharm is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy¬†(always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 3.12 means the investor is paying €3.12¬†for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Lavipharm S.A:

  • The EOD is 3.493. Based on the equity, the company is fair priced.
  • The MRQ is 3.124. Based on the equity, the company is fair priced.
  • The TTM is 3.124. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD3.493MRQ3.124+0.369
MRQ3.124TTM3.1240.000
TTM3.124YOY1.600+1.524
TTM3.1245Y-2.810+5.934
5Y-2.81010Y-1.796-1.014
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Lavipharm S.A compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.0150.0150%0.299-95%0.074-80%0.025-42%
Book Value Per Share--0.2550.2550%0.240+6%0.055+361%-0.082+132%
Current Ratio--1.2751.2750%0.997+28%1.169+9%0.916+39%
Debt To Asset Ratio--0.6270.6270%0.647-3%0.999-37%1.293-51%
Debt To Equity Ratio--1.6851.6850%1.835-8%0.704+139%0.352+379%
Dividend Per Share----0%-0%-0%-0%
Eps--0.0110.0110%0.005+124%0.014-21%-0.002+119%
Free Cash Flow Per Share---0.023-0.0230%-0.192+742%-0.048+112%-0.048+112%
Free Cash Flow To Equity Per Share---0.023-0.0230%0.099-123%0.019-219%0.019-219%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---1.038--------
Intrinsic Value_10Y_min---0.878--------
Intrinsic Value_1Y_max---0.075--------
Intrinsic Value_1Y_min---0.073--------
Intrinsic Value_3Y_max---0.248--------
Intrinsic Value_3Y_min---0.234--------
Intrinsic Value_5Y_max---0.448--------
Intrinsic Value_5Y_min---0.409--------
Market Cap149402520.000+11%133623311.672133623311.6720%64461496.320+107%82255433.598+62%52497416.439+155%
Net Profit Margin--0.0370.0370%0.018+103%0.063-42%-0.025+169%
Operating Margin----0%0.088-100%0.091-100%0.009-100%
Operating Ratio--1.4621.4620%1.529-4%1.283+14%1.410+4%
Pb Ratio3.493+11%3.1243.1240%1.600+95%-2.810+190%-1.796+157%
Pe Ratio79.852+11%71.41871.4180%77.292-8%49.966+43%27.045+164%
Price Per Share0.890+11%0.7960.7960%0.384+107%0.490+62%0.313+155%
Price To Free Cash Flow Ratio-38.978-12%-34.861-34.8610%-1.998-94%12.996-368%6.498-636%
Price To Total Gains Ratio59.953+11%53.62153.6210%1.284+4077%28.169+90%20.184+166%
Quick Ratio--0.6060.6060%0.708-14%0.699-13%0.578+5%
Return On Assets--0.0160.0160%0.007+123%0.041-61%0.020-20%
Return On Equity--0.0440.0440%0.021+111%0.013+239%0.006+579%
Total Gains Per Share--0.0150.0150%0.299-95%0.074-80%0.025-42%
Usd Book Value--45802393.00045802393.0000%43133710.200+6%9939237.080+361%-14805299.590+132%
Usd Book Value Change Per Share--0.0160.0160%0.320-95%0.079-80%0.027-42%
Usd Book Value Per Share--0.2730.2730%0.257+6%0.059+361%-0.088+132%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps--0.0120.0120%0.005+124%0.015-21%-0.002+119%
Usd Free Cash Flow---4104759.700-4104759.7000%-34557943.000+742%-6968774.660+70%-3484387.330-15%
Usd Free Cash Flow Per Share---0.024-0.0240%-0.206+742%-0.052+112%-0.052+112%
Usd Free Cash Flow To Equity Per Share---0.024-0.0240%0.106-123%0.021-219%0.021-219%
Usd Market Cap159995158.668+11%143097204.470143097204.4700%69031816.409+107%88087343.841+62%56219483.265+155%
Usd Price Per Share0.953+11%0.8520.8520%0.411+107%0.525+62%0.335+155%
Usd Profit--2003653.9002003653.9000%893130.600+124%2553025.600-22%-364641.450+118%
Usd Revenue--54539866.10054539866.1000%49268896.300+11%44525023.480+22%38718603.680+41%
Usd Total Gains Per Share--0.0160.0160%0.320-95%0.079-80%0.027-42%
 EOD+5 -3MRQTTM+0 -0YOY+23 -105Y+15 -1810Y+19 -14

3.2. Fundamental Score

Let's check the fundamental score of Lavipharm S.A based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1579.852
Price to Book Ratio (EOD)Between0-13.493
Net Profit Margin (MRQ)Greater than00.037
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.606
Current Ratio (MRQ)Greater than11.275
Debt to Asset Ratio (MRQ)Less than10.627
Debt to Equity Ratio (MRQ)Less than11.685
Return on Equity (MRQ)Greater than0.150.044
Return on Assets (MRQ)Greater than0.050.016
Total3/10 (30.0%)

3.3. Technical Score

Let's check the technical score of Lavipharm S.A based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.684
Ma 20Greater thanMa 500.931
Ma 50Greater thanMa 1000.889
Ma 100Greater thanMa 2000.888
OpenGreater thanClose0.892
Total4/5 (80.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in EUR. All numbers in thousands.

Summary
Total Assets114,786
Total Liabilities72,016
Total Stockholder Equity42,737
 As reported
Total Liabilities 72,016
Total Stockholder Equity+ 42,737
Total Assets = 114,786

Assets

Total Assets114,786
Total Current Assets45,652
Long-term Assets69,134
Total Current Assets
Cash And Cash Equivalents 8,435
Short-term Investments 3
Net Receivables 21,697
Inventory 14,833
Other Current Assets 1
Total Current Assets  (as reported)45,652
Total Current Assets  (calculated)44,969
+/- 683
Long-term Assets
Property Plant Equipment 19,543
Intangible Assets 44,542
Long-term Assets Other 1
Long-term Assets  (as reported)69,134
Long-term Assets  (calculated)64,086
+/- 5,048

Liabilities & Shareholders' Equity

Total Current Liabilities35,801
Long-term Liabilities36,215
Total Stockholder Equity42,737
Total Current Liabilities
Short Long Term Debt 7,993
Accounts payable 9,955
Other Current Liabilities 1
Total Current Liabilities  (as reported)35,801
Total Current Liabilities  (calculated)17,949
+/- 17,852
Long-term Liabilities
Long term Debt 12,697
Capital Lease Obligations Min Short Term Debt11,683
Long-term Liabilities Other 3,454
Long-term Liabilities  (as reported)36,215
Long-term Liabilities  (calculated)27,834
+/- 8,381
Total Stockholder Equity
Total Stockholder Equity (as reported)42,737
Total Stockholder Equity (calculated)0
+/- 42,737
Other
Capital Stock50,361
Common Stock Shares Outstanding 167,868
Net Debt 12,255
Net Invested Capital 63,427
Net Working Capital 9,851
Property Plant and Equipment Gross 41,032



Balance Sheet

Currency in EUR. All numbers in thousands.

 Trend2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-31
> Total Assets 
83,824
82,379
48,177
44,808
41,897
49,422
50,638
52,741
114,168
114,786
114,786114,16852,74150,63849,42241,89744,80848,17782,37983,824
   > Total Current Assets 
19,818
20,988
21,267
19,866
18,941
21,085
23,342
25,961
45,600
45,652
45,65245,60025,96123,34221,08518,94119,86621,26720,98819,818
       Cash And Cash Equivalents 
2,437
2,057
1,675
2,348
1,842
1,732
1,932
1,638
18,243
8,435
8,43518,2431,6381,9321,7321,8422,3481,6752,0572,437
       Short-term Investments 
0
0
0
44
12
0
0
0
1
3
310001244000
       Net Receivables 
12,249
12,945
13,511
11,294
11,617
12,298
9,883
15,665
14,126
21,697
21,69714,12615,6659,88312,29811,61711,29413,51112,94512,249
       Inventory 
3,525
4,358
5,527
5,590
4,842
6,063
8,419
9,240
10,436
14,833
14,83310,4369,2408,4196,0634,8425,5905,5274,3583,525
       Other Current Assets 
1,607
1,628
453
590
628
949
769
635
960
1
19606357699496285904531,6281,607
   > Long-term Assets 
0
0
0
0
0
0
27,156
26,780
68,568
69,134
69,13468,56826,78027,156000000
       Property Plant Equipment 
23,024
22,404
18,595
15,276
15,329
17,188
16,422
17,488
17,099
19,543
19,54317,09917,48816,42217,18815,32915,27618,59522,40423,024
       Long Term Investments 
225
132
0
0
0
0
0
0
0
0
00000000132225
       Intangible Assets 
9,684
8,639
2,889
3,096
2,667
3,413
3,492
3,136
46,195
44,542
44,54246,1953,1363,4923,4132,6673,0962,8898,6399,684
       Long-term Assets Other 
0
0
0
0
0
0
855
827
650
1
1650827855000000
> Total Liabilities 
132,788
146,799
80,002
64,727
61,426
63,824
62,941
62,678
73,890
72,016
72,01673,89062,67862,94163,82461,42664,72780,002146,799132,788
   > Total Current Liabilities 
78,765
87,053
41,905
19,497
14,666
17,355
18,803
23,232
45,740
35,801
35,80145,74023,23218,80317,35514,66619,49741,90587,05378,765
       Short-term Debt 
31,696
40,502
60
1,111
539
1,239
1,133
1,404
0
0
001,4041,1331,2395391,1116040,50231,696
       Short Long Term Debt 
31,696
40,502
60
1,111
1,036
0
3,537
21,291
21,604
7,993
7,99321,60421,2913,53701,0361,1116040,50231,696
       Accounts payable 
4,040
5,207
2,125
2,215
2,575
4,036
2,742
4,162
6,304
9,955
9,9556,3044,1622,7424,0362,5752,2152,1255,2074,040
       Other Current Liabilities 
9,894
7,697
6,953
5,644
4,206
4,386
4,124
4,223
-1
1
1-14,2234,1244,3864,2065,6446,9537,6979,894
   > Long-term Liabilities 
0
0
0
0
0
0
43,336
21,612
28,115
36,215
36,21528,11521,61243,336000000
       Long term Debt Total 
0
0
0
0
0
0
35,127
32,568
14,945
0
014,94532,56835,127000000
       Capital Lease Obligations Min Short Term Debt
-31,696
-40,502
-60
-1,111
-539
-1,239
10,031
10,529
11,505
11,683
11,68311,50510,52910,031-1,239-539-1,111-60-40,502-31,696
       Other Liabilities 
5,630
8,269
6,427
5,476
8,237
8,701
7,847
6,337
0
0
006,3377,8478,7018,2375,4766,4278,2695,630
       Deferred Long Term Liability 
21,383
21,622
1,281
1,080
817
952
1,334
1,825
0
0
001,8251,3349528171,0801,28121,62221,383
> Total Stockholder Equity
-25,997
-35,849
-31,825
-19,919
-19,529
-14,402
-12,303
-9,976
40,278
42,737
42,73740,278-9,976-12,303-14,402-19,529-19,919-31,825-35,849-25,997
   Common Stock
51,081
51,081
51,081
51,081
51,081
51,081
51,081
51,081
50,361
0
050,36151,08151,08151,08151,08151,08151,08151,08151,081
   Retained Earnings -32,591-17,496-159,959-161,682-164,277-169,604-169,907-160,385-180,716-173,642
   Capital Surplus 
0
0
84,418
84,418
84,418
84,418
84,418
84,418
7,413
0
07,41384,41884,41884,41884,41884,41884,41800
   Treasury Stock0000000000
   Other Stockholders Equity 
12,146
9,368
-6,939
14,489
14,576
14,376
14,508
14,484
0
0
0014,48414,50814,37614,57614,489-6,9399,36812,146



Balance Sheet

Currency in EUR. All numbers in thousands.




Cash Flow

Currency in EUR. All numbers in thousands.




Income Statement

Currency in EUR. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue50,929
Cost of Revenue-27,734
Gross Profit23,19623,195
 
Operating Income (+$)
Gross Profit23,196
Operating Expense-46,749
Operating Income4,181-23,553
 
Operating Expense (+$)
Research Development430
Selling General Administrative2,624
Selling And Marketing Expenses-
Operating Expense46,7493,054
 
Net Interest Income (+$)
Interest Income270
Interest Expense-2,267
Other Finance Cost-0
Net Interest Income-1,997
 
Pretax Income (+$)
Operating Income4,181
Net Interest Income-1,997
Other Non-Operating Income Expenses-
Income Before Tax (EBT)3,2474,181
EBIT - interestExpense = -2,267
1,871
4,138
Interest Expense2,267
Earnings Before Interest and Taxes (EBIT)-5,514
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax3,247
Tax Provision-1,251
Net Income From Continuing Ops1,9961,996
Net Income1,871
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-1,997
 

Technical Analysis of Lavipharm
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Lavipharm. The general trend of Lavipharm is BULLISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Lavipharm's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (71.4%) Bearish trend (-71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Lavipharm S.A.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 0.94 < 0.99413 < 1.0052903225807.

The bearish price targets are: 0.889 > 0.78 > 0.78.

Tweet this
Lavipharm S.A Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging¬†trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Lavipharm S.A. The current mas is .

The long score for the Moving Averages is 12/14.
The longshort score for the Moving Averages is 10/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Lavipharm S.A Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a¬†lagging momentum¬†indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Lavipharm S.A. The current macd is 0.00017248.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Lavipharm price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Lavipharm. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Lavipharm price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Lavipharm S.A Daily Moving Average Convergence/Divergence (MACD) ChartLavipharm S.A Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Lavipharm S.A. The current adx is 17.05.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Lavipharm shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Lavipharm S.A Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows¬†the current trend.
  • Shows¬†potential entry signals.
  • Shows¬†¬†potential exit signals.
  • Can be used to place¬†trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Lavipharm S.A. The current sar is 0.926.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Lavipharm S.A Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum¬†indicator, meaning the signals are instant.
  • Ranges¬†between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Lavipharm S.A. The current rsi is 42.68. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending down: The RSI is trending down. -1
Lavipharm S.A Daily Relative Strength Index (RSI) ChartLavipharm S.A Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading¬†momentum¬†indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges¬†between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Lavipharm S.A. The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Lavipharm price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Lavipharm S.A Daily Stochastic Oscillator ChartLavipharm S.A Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,¬†the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Lavipharm S.A. The current cci is -138.90544299.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Lavipharm S.A Daily Commodity Channel Index (CCI) ChartLavipharm S.A Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Lavipharm S.A. The current cmo is -28.90480187.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Lavipharm S.A Daily Chande Momentum Oscillator (CMO) ChartLavipharm S.A Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and¬†-100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Lavipharm S.A. The current willr is -72.47706422.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Lavipharm is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Lavipharm S.A Daily Williams %R ChartLavipharm S.A Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold¬†

Score

Let's take a look at the Bollinger Bands of Lavipharm S.A.

Lavipharm S.A Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Lavipharm S.A. The current atr is 0.03045407.

Lavipharm S.A Daily Average True Range (ATR) ChartLavipharm S.A Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Lavipharm S.A. The current obv is 15,643,014.

Lavipharm S.A Daily On-Balance Volume (OBV) ChartLavipharm S.A Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Lavipharm S.A. The current mfi is 24.16.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Lavipharm S.A Daily Money Flow Index (MFI) ChartLavipharm S.A Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Lavipharm S.A.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-26BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-30RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-27RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-07CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-13WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-08CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-15STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-16STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-17RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-04-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-19MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-22CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-25CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-05-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-05-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-05-15BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-05-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-20RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-05-21STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-05-22RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-23SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-05-24STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-05-27STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-05-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-06-03WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-06-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-06-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-06-07CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-06-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-06-12WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-06-14STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside

6.3. Candlestick Patterns

Lavipharm S.A Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Lavipharm S.A based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.684
Ma 20Greater thanMa 500.931
Ma 50Greater thanMa 1000.889
Ma 100Greater thanMa 2000.888
OpenGreater thanClose0.892
Total4/5 (80.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Lavipharm with someone you think should read this too:
  • Are you bullish or bearish on Lavipharm? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Lavipharm? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Lavipharm S.A

I send you an email if I find something interesting about Lavipharm S.A.


Comments

How you think about this?

Leave a comment

Stay informed about Lavipharm S.A.

Receive notifications about Lavipharm S.A in your mailbox!